Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (1133)	4/14/2000 9:20:00 AM
From: Ron	Read Replies (1) \| Respond to of 1386

Thank you Dr. Tracy for your reply. What is your take on the pr for phase 2 cohort 3 results for HU-211? Did the pr appear to show "mixed" results because the same neurological outcome was not the attained at 6 months as it was in the first 2 cohorts? If so, do you feel this will be a negative for PARS? I would also be grateful for your intake on PARS beginning phase 3 in Europe.... And finally what is your opinion concerning Dr. Waskal? Is this a sign of a future partnership for Tamoxofin? THANK YOU KINDLY, Dr. Tracy, as your opinion is greatly respected by me. Take care...Ron